CompletedInterventionalPhase 2Updated Nov 30, 2006
Study of Difluprednate in the Treatment of Uveitis | NCT00501579 | Trialant
CompletedInterventionalPhase 3Updated Aug 29, 2008
Study of Difluprednate in the Treatment of Uveitis
ClinicalTrials.gov ID
NCT00501579
Lead Sponsor
Sirion Therapeutics, Inc.INDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 3
Last Update Posted
Aug 29, 2008Estimated
Brief Summary
The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.
Uveitis
Difluprednate
Prednisolone Acetate
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Diagnosis of endogenous anterior uveitis in at least 1 eye
Exclusion Criteria:
Presence of intermediate uveitis, posterior uveitis or panuveitis
Corneal abrasion
Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease
Allergy to similar drugs, such as other corticosteroids